---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-001642"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T06:43:01.206975+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aytu BioPharma Q2 FY2023 revenue $26.3M (+14% YoY); second consecutive positive adjusted EBITDA $0.7M

## Summary
- Net revenue $26.3M, up 14% YoY; Rx segment $18.0M (+23%) driven by 95% growth in pediatric products.
- Adjusted EBITDA positive $0.7M vs $(7.6)M loss in year-ago quarter; second consecutive positive quarter.
- Net loss $(6.7)M ($2.15 per share) improved from $(11.5)M ($8.74 per share) in Q2 FY2022.
- Gross margin expanded to 66% from 53% YoY; suspension of clinical programs expected to save over $20M.
- Extended interest-only period on Avenue loan to Jan 2024; 1-for-20 reverse stock split regained Nasdaq compliance.

## SEC filing metadata
- accession: 0001558370-23-001642
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000155837023001642/0001558370-23-001642-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000155837023001642/aytu-20230221x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-001642
- JSON: https://secwatch.observer/filing/0001558370-23-001642.json
- Plain text: https://secwatch.observer/filing/0001558370-23-001642.txt

## Key facts
- Earnings Releases
  AYTU BIOPHARMA, INC reported the quarter ended December 31, 2022 results: revenue $26.3 million.
  - Period: the quarter ended December 31, 2022
  - Revenue: $26.3 million
  - Result: reported results
  source text: ​ --- EX-99.1 (EX-99.1) --- ​ ​ Aytu BioPharma Reports Second Quarter of Fiscal Year 2023 ​ Second Consecutive Quarter of Positive Adjusted EBITDA ​ Quarterly Net Revenue of $26.3 Million Driven by 23% Growth in Rx Segment ​ Company to Host Conference Call Today at 5:00 pm ET ​ ENGLEWOOD, CO / February 21, 2023 / Aytu BioPharma, Inc. (the Company or “Aytu”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1385818/000155837023001642/0001558370-23-001642-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.